Asai S, et al. - In this cross-sectional study, investigators assessed the impact of methotrexate (MTX) on gastrointestinal (GI) symptoms in patients with rheumatoid arthritis (RA). Study participants included 529 consecutive patients with RA who received oral MTX between April 1, 2017, and September 30, 2017. They assessed GI symptoms using the Gastrointestinal Symptom Rating Scale, and prevalence of GI symptoms was compared between patients receiving low- (≤ 8 mg) and high (> 8 mg) weekly MTX doses. They found no variation in the prevalence of indigestion, diarrhea, or constipation between groups. They observed that those in the high-dose MTX group exhibited a higher prevalence of reflux and abdominal pain vs those in the low-dose MTX group. The ORs for reflux and abdominal pain among high-dose MTX group members were similar to those using nonsteroidal anti-inflammatory drugs.